Cyril Amarchand Mangaldas, Trilegal and White & Case have counselled parties involved in Anthem Biosciences’ initial public offering, raising INR33.95 billion (USD395 million) on the Bombay Stock Exchange and the National Stock Exchange of India.
Anthem Biosciences’ shares were listed on both the BSE and NSE on 21 July 2025. The IPO was oversubscribed 63.86 times and listed at a premium of 26.85% above the issue price of INR570 per share. Certain shareholders also offered existing shares for sale alongside the IPO.
Trilegal acted for Anthem Biosciences and certain shareholders on India law. Partner Richa Choudhary led the team with the support of counsel Maitreya Rajurkar and Avanti Kale, senior associates Sanya Chaudhari and Shivayana Balodia, as well as associates Anushri Maskara, Siddhant Mishra and Anay Jain.
Cyril Amarchand Mangaldas advised the book running lead managers — JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India) — in connection with the IPO. White & Case acted as international legal counsel.
CAM partners Reuben Chacko and Vartika Jain led the team, with assistance from associates Bhaskar Kumar, Dhruv Sharma, Prakhar Jain, Joe George and Rakshitha V.
Anthem Biosciences is an innovation-driven, technology-focused contract research, development and manufacturing company, with integrated operations across drug discovery, development and production.
